U.S. Percutaneous Coronary Intervention Devices Market 8.15%

Market Outlook

By 2035, the U.S. Percutaneous Coronary Intervention Devices Market is expected to reach approximately USD 11.71 billion, growing at a CAGR of 8.15% during the forecast period 2026–2035. The market was valued at USD 5.35 billion in 2025, with historical analysis from 2021 to 2024. Values in this report are expressed in USD billions.

The U.S. percutaneous coronary intervention devices industry sits at the center of acute myocardial infarction care and elective coronary revascularization. The market includes coronary stents and scaffolds, angioplasty and drug-coated balloons, guidewires, guiding and diagnostic support catheters, microcatheters, lesion preparation systems, thrombectomy products, intravascular imaging and physiology technologies, vascular closure devices, and percutaneous circulatory support used during high-risk PCI. The estimate excludes pharmaceutical therapy, coronary artery bypass grafting products, hospital procedure charges, and diagnostic-only equipment not used in a PCI workflow. This scope reflects the commercial value pool that device manufacturers, distributors, cath lab operators, investors, and hospital procurement teams actively evaluate.

Demand is anchored by the scale of coronary artery disease in the United States. Coronary heart disease caused more than 371,000 deaths in 2022, approximately 20 million adults live with coronary heart disease, and a myocardial infarction occurs about every 40 seconds. The annual direct and indirect economic burden of coronary heart disease has been estimated at more than USD 129 billion. These figures translate into persistent utilization of emergency PCI, staged revascularization, elective intervention, repeat treatment for restenosis, and complex procedures in patients with diabetes, chronic kidney disease, prior bypass surgery, severe calcification, multivessel disease, and impaired ventricular function.

The commercial profile of the market is shifting from routine stent placement toward higher-value precision PCI. Contemporary procedures increasingly combine intravascular ultrasound or optical coherence tomography, pressure-based or angiography-derived physiology, specialty balloons, atherectomy, intravascular lithotripsy, mechanical support, and advanced closure. Approximately 6.66 million PCIs were captured across participating U.S. registry sites from 2013 through 2022, equivalent to more than 660,000 procedures per year within the registry footprint. Procedure count is important, but revenue growth is increasingly determined by device intensity per case and the mix of complex, calcified, left main, bifurcation, chronic total occlusion, and high-risk interventions.

The historical market expanded from approximately USD 4.08 billion in 2021 to USD 4.95 billion in 2024. Recovery in elective cath lab activity, strong drug-eluting stent replacement demand, accelerated adoption of intravascular lithotripsy, growth in imaging-guided PCI, and expanding use of mechanical circulatory support contributed to this progression. The market reached USD 5.35 billion in 2025 as hospitals prepared for stronger guideline-driven imaging adoption, expanded radial-first workflows, increased complex PCI capacity, and introduced the first FDA-approved coronary drug-coated balloon into treatment pathways for in-stent restenosis.

Introduction

According to the U.S. Percutaneous Coronary Intervention Devices Market Report, PCI remains one of the most operationally important and economically scrutinized procedure categories in American cardiovascular care. It is performed across emergency, inpatient, hospital outpatient, and selected ambulatory settings, and it directly affects mortality, length of stay, readmission risk, cath lab throughput, and downstream medication management. The procedure is also highly standardized from a coding perspective but clinically heterogeneous, which means hospitals must manage a broad device inventory while maintaining rapid availability for unplanned acute cases.

The market is supported by a large, aging, and increasingly complex patient population. The U.S. population aged 65 and older reached approximately 61.2 million in 2024, and more than half of PCI procedures have historically been performed in patients aged 65 or above. Older patients are more likely to present with diffuse disease, calcification, renal dysfunction, frailty, prior revascularization, and bleeding risk. At the same time, diabetes, obesity, hypertension, and dyslipidemia continue to expand the pool of patients requiring coronary evaluation and intervention. More than 122 million U.S. adults have hypertension, adult obesity prevalence is above 40%, and total diabetes affects a substantial share of the adult population.

PCI economics are increasingly shaped by the site of service. Hospital inpatient care remains essential for STEMI, shock, high-risk anatomy, and medically unstable patients. Hospital outpatient departments manage a large share of elective and lower-acuity cases, while ambulatory surgery centers are emerging selectively following Medicare coverage expansion for certain PCI procedures. From 2020 through 2022, more than 408,000 Medicare beneficiaries underwent outpatient PCI in one national analysis, although only 1.8% of those procedures occurred in ASCs. This indicates that outpatient migration is real but remains constrained by patient selection, emergency backup requirements, capital needs, and payer contracting.

U.S. hospitals operate more than 5,100 community hospitals, over 900,000 staffed beds, and tens of millions of annual admissions. Within this infrastructure, the cath lab is a high-cost, high-throughput environment where clinical preference, vendor standardization, consignment inventory, service support, and reimbursement must be balanced. Procurement decisions increasingly assess the complete episode: access strategy, contrast load, procedure time, number of devices opened, bailout risk, post-procedure bed use, discharge timing, and likelihood of repeat intervention. Suppliers that improve procedural predictability and reduce avoidable resource use can command stronger strategic positions than suppliers competing only on unit price.

From 2026 to 2035, the central market theme will be the conversion of PCI from angiography-led treatment to data-guided coronary intervention. The 2025 U.S. acute coronary syndromes guideline reinforced radial access and elevated intravascular imaging for complex lesions. This creates a direct commercial pull for IVUS and OCT catheters, co-registration software, physiology tools, vessel preparation products, and workflow platforms that convert imaging into treatment decisions. The market will continue to reward products that help operators select the right lesion, prepare calcium effectively, size and optimize the implant, minimize contrast, and document procedural quality.

Key Market Drivers: What’s Fueling the U.S. Percutaneous Coronary Intervention Devices Market?

The first major driver is the persistent burden of coronary heart disease and acute coronary syndromes. Cardiovascular disease accounted for more than 941,000 U.S. deaths in 2022, with coronary heart disease representing the largest share. Approximately 605,000 first heart attacks and 200,000 recurrent attacks are estimated to occur in a typical year. Even with improved prevention and medical therapy, the absolute number of older adults, diabetes prevalence, and survival after prior cardiovascular events continue to expand the population requiring diagnostic catheterization, urgent PCI, staged revascularization, and repeat intervention.

A second driver is the rising complexity of the treated patient. Routine focal lesions can often be managed with a straightforward wire, balloon, and drug-eluting stent. Revenue growth, however, is increasingly concentrated in calcified lesions, left main disease, bifurcations, long diffuse disease, chronic total occlusions, degenerated vein grafts, and patients with severely reduced ventricular function. These cases consume more guidewires, microcatheters, specialty balloons, imaging catheters, plaque modification devices, closure systems, and hemodynamic support. The result is a larger device basket per procedure even when aggregate PCI volumes grow only moderately.

A third driver is the guideline-supported shift toward radial access and intravascular imaging. Radial access increased from about 20.3% of U.S. PCI procedures in 2013 to 57.5% in 2022. This change supports demand for radial sheaths, hydrophilic access products, smaller-profile guide catheters, compression devices, and equipment designed for same-day discharge pathways. In parallel, intravascular imaging received stronger clinical endorsement for complex PCI. Because imaging remains underused relative to its evidence base, the addressable opportunity is substantial for systems that reduce setup time, simplify interpretation, and integrate imaging findings with stent selection and optimization.

A fourth driver is the rapid growth of coronary calcium treatment. Calcification increases with age, diabetes, and chronic kidney disease and is associated with stent underexpansion, dissection, perforation, and repeat revascularization. Rotational and orbital atherectomy remain important, but intravascular lithotripsy has created a new premium device category because it can modify deep and superficial calcium using a balloon-based workflow. The USD 13.1 billion acquisition of Shockwave Medical in 2024 demonstrated the strategic value assigned to calcium modification and intensified investment in next-generation IVL, laser-based lithotripsy, and integrated lesion preparation platforms.

A fifth driver is the expansion of treatment options for in-stent restenosis. The first U.S. coronary drug-coated balloon approval in 2024 established a device-based alternative to placing another metal layer in selected patients with restenosis. This is commercially significant because the installed base of prior stents is large, patients frequently return with recurrent disease, and multilayer stenting can complicate future treatment. Drug-coated balloons are expected to stimulate demand for vessel preparation, imaging, specialty balloons, and post-procedure follow-up while creating a new competitive category within coronary intervention.

A sixth driver is the migration of suitable PCI cases toward outpatient and same-day discharge models. Hospitals are attempting to reduce bed utilization and improve cath lab economics, while payers are encouraging lower-cost sites of care when safety criteria are met. Radial access, improved closure, lower-profile devices, standardized bleeding-risk assessment, and better recovery protocols support this transition. The fastest commercial beneficiaries will be products that lower procedural variability and fit streamlined outpatient workflows without sacrificing bailout capability.

A seventh driver is reimbursement and quality measurement. Medicare maintains established coding pathways for angioplasty, stenting, atherectomy, thrombectomy, coronary imaging, physiology, and circulatory support, although payment packaging and site-of-service rules influence hospital economics. Elective outpatient PCI is also evaluated through episode-based cost measures, increasing pressure on clinicians and facilities to control total allowed cost rather than optimize a single device line item. Manufacturers that provide economic evidence, coding support, utilization analytics, and quality improvement tools can materially influence value-analysis decisions.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. PCI devices market is moving toward a “see, prepare, treat, and confirm” model. Angiography alone provides a lumen silhouette but limited information on plaque morphology, calcium depth, vessel dimensions, stent expansion, or the physiological importance of a stenosis. Leading manufacturers are therefore building procedure ecosystems that connect imaging, physiology, lesion preparation, implants, and post-deployment optimization. The strongest platforms reduce the number of disconnected consoles, shorten training time, and provide a consistent workflow across routine and complex cases.

Intravascular imaging is a primary innovation frontier. High-definition IVUS, faster OCT pullback, automated vessel measurements, calcium characterization, and AI-assisted interpretation are making imaging more actionable. Co-registration with angiography allows operators to map plaque and physiology to a precise vessel location. The commercial opportunity is not limited to the imaging catheter; it includes capital systems, software upgrades, service contracts, disposable pullback components, and pull-through demand for stents and vessel preparation devices selected from the imaging findings.

Coronary physiology is becoming less dependent on hyperemic pressure wires. Traditional fractional flow reserve and resting indices remain established, but angiography-derived FFR and AI-enabled vessel analysis can reduce wire use, medication requirements, and procedural disruption in selected settings. In 2025, clinical evidence showed that an AI-powered angiographic FFR approach could achieve outcomes comparable with IVUS-guided decision-making in a defined population. Broader adoption will depend on reproducibility, integration with cath lab imaging systems, payer recognition, and physician confidence in software-generated measurements.

Lesion preparation is entering a multi-technology phase. Rotational atherectomy, orbital atherectomy, laser atherectomy, cutting and scoring balloons, ultra-high-pressure balloons, and IVL each address different lesion characteristics. Hospitals increasingly want algorithms that guide device selection rather than simply expanding inventory. Imaging-based calcium scoring and standardized preparation pathways can improve stent expansion while controlling cost. Competition will intensify around lower-profile delivery, broader vessel sizes, more pulses or energy capacity, improved crossability, and easier use through radial access.

Coronary implants are evolving through thinner struts, enhanced deliverability, improved polymer strategies, shorter dual-antiplatelet therapy evidence, and specialty designs for large proximal vessels or difficult anatomy. Drug-eluting stents will remain the dominant implant category, but growth will be slower than in imaging and calcium modification because pricing is mature and vendor contracts are highly competitive. Drug-coated balloons, covered stents, and future bioresorbable platforms create differentiated opportunities where conventional DES treatment is suboptimal.

High-risk PCI support is another strategic area. Percutaneous ventricular assist devices and intra-aortic balloon pumps are used selectively to maintain hemodynamics during complex intervention or cardiogenic shock management. Growth depends on evidence, patient selection, complication reduction, and hospital protocol development. Manufacturers are investing in smaller access profiles, smarter consoles, improved purge or anticoagulation management, and integration with shock teams. Because support devices are expensive and clinically consequential, procurement is strongly tied to outcomes registries and service-line governance.

Workflow innovation also includes contrast-reduction systems, radiation management, robotic assistance, CT-based planning, digital inventory control, and remote technical support. These technologies address practical cath lab problems: renal risk, staff exposure, inconsistent technique, product expiration, and shortage of experienced personnel. Robotic PCI adoption remains limited, but the longer-term value proposition includes precise device movement, geographic reach, and tele-proctoring. The winning systems will demonstrate that automation improves throughput or outcomes rather than adding another layer of capital expense.

Segmentation Insights

The U.S. Percutaneous Coronary Intervention Devices Market is segmented on the basis of product category, clinical application, technology and procedural guidance, end user, and region.

By Product Category

Coronary stents and scaffolds represent the largest established product group and account for approximately one-third of 2025 market revenue. Drug-eluting stents dominate because they reduce restenosis and repeat revascularization compared with older bare-metal platforms. U.S. demand is concentrated in thin-strut, highly deliverable DES systems with broad size matrices and evidence supporting complex anatomy or high-bleeding-risk patients. Covered stents serve a smaller but critical bailout market for perforation and selected graft lesions. Bioresorbable scaffolds remain an innovation opportunity rather than a mainstream revenue source because long-term safety, deliverability, and implantation technique must improve before broad adoption.
Balloon catheters include standard PTCA balloons, non-compliant balloons, semi-compliant predilation balloons, scoring and cutting balloons, ultra-high-pressure balloons, perfusion balloons, and drug-coated balloons. The category benefits from recurring use because multiple balloons may be opened in a single complex case. Growth is strongest in specialty vessel preparation and drug delivery rather than conventional predilation. The 2024 approval of a paclitaxel-coated coronary balloon for in-stent restenosis established a new U.S. growth pathway and is expected to increase the use of imaging and structured lesion preparation before drug delivery.
Guidewires, guide catheters, microcatheters, and access devices form the procedural backbone of PCI. Workhorse wires provide stable recurring demand, while specialty wires and microcatheters command premium pricing in chronic total occlusion, tortuous anatomy, bifurcations, and heavily calcified lesions. Radial-first practice is increasing demand for hydrophilic sheaths, slender guide systems, support catheters, guide-extension devices, and compression products. Vendor success depends heavily on physician preference, availability across sizes and tip loads, dependable supply, and hands-on training because performance differences become most visible in difficult anatomy.
Plaque modification and thrombus management devices are among the fastest-growing categories. Rotational atherectomy, orbital atherectomy, excimer laser, intravascular lithotripsy, scoring balloons, thrombectomy catheters, and embolic protection products are used to improve deliverability, stent expansion, or thrombus control. Intravascular lithotripsy is the principal premium growth engine, while atherectomy remains essential in uncrossable or undilatable lesions. Routine aspiration thrombectomy is not broadly favored, but selective use persists in high-thrombus-burden cases. The category is highly influenced by training, complication management, and imaging-based case selection.
Intravascular imaging and coronary physiology devices include IVUS catheters, OCT catheters, pressure wires, Doppler wires, angiography-derived physiology software, and integrated guidance consoles. This segment is expected to grow faster than the total market because the 2025 acute coronary syndromes guideline strengthened the role of imaging in complex PCI. Adoption remains limited by workflow friction, capital availability, interpretation confidence, and payment packaging. Systems that automate measurements and integrate with angiography can expand use beyond academic centers into community hospitals and high-volume outpatient cath labs.
Vascular closure and hemodynamic support devices serve distinct but economically important needs. Radial compression devices support same-day discharge, while femoral closure systems remain necessary for larger-bore access, complex interventions, and mechanical support. Percutaneous ventricular assist devices, intra-aortic balloon pumps, and related cannulas or access kits create high revenue per case but are used in a limited patient subset. Growth will depend on evidence-based high-risk PCI protocols, shock program expansion, access-site complication reduction, and hospital ability to manage the full episode of care.

By Clinical Application

ST-elevation myocardial infarction PCI is the most time-sensitive application and requires immediate availability of stents, wires, aspiration capability, closure, and bailout products. The annual incidence of first and recurrent myocardial infarction exceeds 800,000 events, although not every patient receives PCI. STEMI device selection prioritizes speed, deliverability, radial access, thrombus management, and avoidance of no-reflow. Regional systems of care, transfer times, 24/7 cath lab staffing, and door-to-balloon performance directly influence device utilization. Growth is moderate in procedure count but stronger in imaging, support, and complete revascularization of significant non-culprit disease.
Non-ST-elevation acute coronary syndrome and unstable angina represent a large and clinically diverse application. Patients often require risk stratification, physiology, intravascular imaging, staged treatment, or multivessel PCI. The 2025 guideline supports complete revascularization strategies and imaging for complex lesions, which increases demand for guidance technologies and adjunct devices. Hospitals value products that enable consistent decision-making across day and night shifts and reduce uncertainty in intermediate lesions, left main disease, and diffuse plaque.
Stable ischemic heart disease and elective PCI is the application most exposed to appropriateness review, medical therapy competition, and site-of-service migration. Procedure growth depends less on population prevalence alone and more on documented ischemia, symptom burden, anatomy, and shared decision-making. Device manufacturers must support physiologic lesion assessment, same-day discharge, low bleeding risk, and efficient inventory use. Elective cases are also the most likely to move from inpatient care to hospital outpatient departments and selected ASCs, creating demand for standardized kits and predictable recovery pathways.
Complex and high-risk indicated PCI is the highest-growth application by device value. It includes left main intervention, multivessel disease, chronic total occlusion, severe calcification, last remaining vessel, prior bypass graft failure, and patients with poor ventricular function or surgical ineligibility. These procedures may require multiple wires, guide extensions, microcatheters, imaging, atherectomy or IVL, specialty stents, large-bore closure, and temporary mechanical support. Health systems are building dedicated CHIP programs because they can retain complex referrals and offer an option to patients who are poor candidates for surgery.
In-stent restenosis and stent failure are emerging as a more distinct commercial application. The large installed base of prior coronary stents creates recurring demand for IVUS or OCT to identify underexpansion, neoatherosclerosis, fracture, edge disease, or multiple metal layers. Treatment may involve high-pressure dilation, scoring or cutting balloons, laser, IVL, repeat DES, or a drug-coated balloon. The introduction of a U.S.-approved coronary drug-coated balloon expands treatment choice and is likely to increase protocol-driven imaging and lesion preparation.

By Technology and Procedural Guidance

Angiography-guided conventional PCI continues to account for the majority of U.S. procedures because it is familiar, fast, and available in every cath lab. It remains appropriate for many straightforward lesions, particularly when anatomy and vessel sizing are clear. However, angiography-only treatment is gradually losing share in complex cases because it may underestimate calcium, diffuse disease, and stent underexpansion. Conventional PCI will remain the volume base of the market, but its revenue mix will shift toward better deliverability and lower-profile devices rather than major platform disruption.
Intravascular imaging-guided PCI is expected to be the fastest-growing guidance segment. IVUS is well suited to vessel sizing, plaque burden, left main evaluation, and stent optimization, while OCT provides high-resolution assessment of tissue, thrombus, dissection, and strut apposition. Imaging-guided workflows can influence virtually every device decision in a case. The commercial barrier is no longer primarily clinical evidence; it is workflow adoption. Automated interpretation, integrated consoles, simplified reimbursement support, and physician education will determine the pace of penetration.
Physiology-guided PCI uses FFR, resting pressure indices, coronary flow assessment, or angiography-derived computational measures to determine whether a lesion is ischemia-producing. The segment supports appropriate patient selection and can prevent unnecessary stenting, which creates a complex commercial effect: fewer low-value implants but higher use of diagnostic disposables and better targeting of multivessel intervention. Angiography-derived physiology may accelerate adoption because it can reduce pressure-wire and hyperemic-drug requirements, although hospitals will require strong validation and seamless integration.
Advanced lesion preparation and calcium modification includes atherectomy, IVL, laser, specialty balloons, and combination strategies. It is expanding rapidly because calcified disease is common in older, diabetic, and renal patients. Imaging is increasingly used to determine calcium arc, depth, length, and fracture before stenting. The segment carries premium pricing but also high training and complication sensitivity. Hospitals will increasingly standardize algorithms to determine when to use IVL, atherectomy, or both, and procurement committees will track device cost against stent expansion, perforation, bailout, and repeat procedure rates.
AI-enabled, robotic, and digitally integrated PCI is an emerging technology layer rather than a mature standalone market. AI supports image interpretation, angiographic physiology, lesion measurement, calcium detection, and procedure planning. Robotic systems can improve device positioning and reduce operator radiation exposure but require capital investment and workflow redesign. CT-to-cath lab integration, remote support, and automated documentation are expected to gain relevance as health systems seek standardized care across multiple facilities. Adoption will be strongest when digital tools demonstrably reduce procedure time, contrast, radiation, or variability.

By End User

Large hospitals and integrated delivery networks are the dominant end users because they manage the greatest share of acute, complex, and high-risk PCI. Enterprise systems negotiate portfolio contracts across stents, balloons, wires, imaging, closure, and capital equipment. Value-analysis committees evaluate clinical evidence, physician preference, supply reliability, rebate structure, and the total cost of a case. Large IDNs can accelerate adoption across multiple sites, but they also exert substantial pricing pressure and may restrict the number of approved vendors in mature categories.
Academic and tertiary heart centers are the principal early adopters of novel PCI technologies. They perform complex left main, CTO, calcified, mechanical-support, and post-bypass interventions and frequently participate in clinical trials or post-market registries. These centers influence national practice through fellowship training, live-case education, publications, and referral protocols. Manufacturers use them to establish evidence and physician advocacy, although procurement often requires rigorous outcomes and conflict-of-interest governance.
Community hospitals provide a large base of routine and emergency PCI demand. Many participate in regional STEMI networks and depend on reliable 24/7 availability, straightforward device setup, and vendor clinical support. Community sites may have less access to advanced imaging or multiple plaque modification platforms, creating an opportunity for integrated systems that reduce complexity. Expansion of complex PCI into community settings will depend on operator volume, surgical backup arrangements, transfer protocols, and the ability to manage complications.
Hospital outpatient departments are gaining share in elective PCI and post-acute staged procedures. They benefit from direct hospital integration, emergency resources, and established payer contracts while allowing same-day discharge for selected patients. Outpatient departments prioritize radial access, closure, low contrast use, predictable recovery, and efficient room turnover. Because payment packaging can limit separate reimbursement for adjunct technologies, manufacturers must demonstrate that higher device cost is offset by fewer complications, shorter stays, or improved procedural success.
Ambulatory surgery centers and specialized outpatient cath labs represent a small but strategically important end-user segment. Medicare coverage of selected PCI procedures has enabled growth, but ASCs still accounted for less than 2% of Medicare outpatient PCI in a 2020–2022 analysis. Expansion will be concentrated in carefully selected elective patients and regions with strong independent cardiology groups. The segment favors compact systems, simplified inventory, transparent pricing, radial-first products, and rapid escalation agreements with nearby hospitals.

Regional Insights: Where the Market is Growing Fastest

The U.S. Percutaneous Coronary Intervention Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance is determined by population scale, age distribution, coronary disease burden, density of PCI-capable hospitals, concentration of academic heart centers, rural transfer networks, payer mix, and adoption of outpatient care. The South is the largest market, while the West is projected to grow fastest through 2035. The Northeast generates high device value per case because of procedure complexity and advanced technology adoption, and the Midwest provides a stable base of mature cath lab demand and medtech expertise.

South

The South is the largest regional market, valued at approximately USD 1.90 billion in 2025 and projected to reach about USD 4.18 billion by 2035, representing a CAGR of roughly 8.20%. The region includes Delaware, the District of Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas. Its leadership is supported by rapid population growth, a large Medicare population, high diabetes and obesity prevalence, substantial heart disease mortality, and expanding hospital systems across major metropolitan corridors.

Texas and Florida are the most commercially important PCI device markets in the South. Texas combines population scale with large cardiac programs in Houston, Dallas–Fort Worth, San Antonio, and Austin. It supports substantial demand for STEMI PCI, complex coronary intervention, imaging, plaque modification, and mechanical support. Florida has one of the largest older-adult populations in the country and a dense network of hospital-based and independent cardiology providers. Its demographic profile supports recurring demand for calcified-lesion treatment, repeat revascularization, radial access products, and same-day elective PCI pathways.

Georgia, North Carolina, Tennessee, Virginia, and Maryland are strong growth states because they combine expanding metropolitan populations with established academic and integrated cardiovascular networks. Atlanta, Charlotte, Raleigh–Durham, Nashville, Richmond, Northern Virginia, Baltimore, and the Washington metropolitan area are important referral and innovation markets. These states are likely to adopt imaging-guided and outpatient PCI faster than many lower-density states because they have the specialist base, capital infrastructure, and payer mix required to support new technology.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia carry a disproportionate burden of cardiovascular risk and mortality. Recent state mortality data show nearly 15,000 heart disease deaths in Alabama and elevated age-adjusted rates across several lower-Mississippi and Appalachian states. These markets generate strong need for acute PCI, but rural distance, workforce shortages, and uneven cath lab access can limit treatment availability. Manufacturers can create value through reliable inventory, transfer-network support, radial and low-contrast technologies, and training that enables community sites to manage more cases safely.

South Carolina and Delaware are smaller markets but benefit from population growth, coastal retirement migration, and proximity to larger referral systems. The District of Columbia has a compact but high-acuity market anchored by academic and federal institutions. Across the South, hospital consolidation is creating larger purchasing organizations that can standardize device platforms across urban hubs and affiliated regional hospitals. The region will remain the largest revenue pool because disease burden and population growth reinforce both acute and elective procedural demand.

West

The West represented approximately USD 1.18 billion in 2025 and is expected to reach about USD 2.75 billion by 2035, reflecting the fastest regional CAGR of approximately 8.83%. The region includes California, Oregon, Washington, Alaska, Hawaii, Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and Wyoming. Growth is supported by population expansion in the Mountain West, a strong technology and venture ecosystem, high adoption of advanced imaging, and integrated delivery networks that can scale standardized PCI protocols.

California is the largest state market in the West and one of the most influential nationally. It combines the country’s largest state population with major academic centers, large nonprofit health systems, and a concentration of medtech and digital health innovators. Recent mortality data recorded more than 62,000 heart disease deaths in the state, indicating the underlying demand base despite comparatively favorable age-adjusted rates. California is a leading adoption market for IVUS, OCT, physiology, robotic systems, AI-enabled analysis, and outpatient coronary workflows, although payer complexity and hospital cost pressure can slow enterprise purchasing.

Arizona, Nevada, Colorado, and Utah are high-growth states. Arizona and Nevada benefit from rapid population growth and retirement migration, creating demand for PCI in older patients with calcified and multivessel disease. Colorado and Utah have younger median populations but strong integrated systems, active technology adoption, and expanding metropolitan catchment areas. These markets are well positioned for radial-first, imaging-guided, and same-day discharge programs. Arizona recorded nearly 15,000 heart disease deaths in recent state data, underscoring the scale of coronary need in the Southwest.

Washington and Oregon have mature hospital networks and a strong orientation toward evidence-based procurement, digital integration, and population health. Adoption can be rapid when technology demonstrates measurable improvement in outcomes or total cost, but value-analysis standards are rigorous. Idaho, Montana, Wyoming, Alaska, and New Mexico are smaller markets with substantial rural access challenges. Device demand is concentrated in regional referral centers, while transfer protocols and telehealth coordination are essential for acute coronary care.

Hawaii is geographically isolated and depends on concentrated tertiary capacity, making supply continuity and inventory planning particularly important. Across the West, manufacturers can gain advantage by integrating clinical devices with cath lab imaging, data analytics, and remote support. The region’s faster forecast growth reflects both demographic expansion and its willingness to adopt platforms that connect pre-procedure CT or angiography, intraprocedural guidance, and post-procedure documentation.

Northeast

The Northeast accounted for approximately USD 1.24 billion in 2025 and is projected to reach about USD 2.63 billion by 2035, corresponding to a CAGR of approximately 7.81%. The region includes New York, New Jersey, Pennsylvania, Massachusetts, Connecticut, Rhode Island, Maine, New Hampshire, Vermont, and Delaware is classified within the South under the Census regional framework used in this report. The Northeast has the highest median age among U.S. regions and a dense concentration of academic medical centers, high-volume PCI hospitals, and specialist referral networks.

New York, Pennsylvania, and New Jersey form the largest commercial cluster. New York City and its surrounding health systems manage high volumes of acute and complex coronary disease, while upstate networks serve broad rural and suburban catchments. Pennsylvania combines major academic programs in Philadelphia and Pittsburgh with large community systems across the state. New Jersey has high population density, a strong commercial payer base, and proximity to leading referral centers. These states support significant demand for imaging-guided PCI, mechanical support, CTO equipment, and advanced calcium modification.

Massachusetts is smaller by population but disproportionately influential because of its academic hospitals, clinical trial infrastructure, and medtech ecosystem. It is an early evaluation market for new imaging, physiology, and digital guidance platforms. Connecticut and Rhode Island have compact provider markets where a limited number of systems can shape statewide purchasing. Maine, New Hampshire, and Vermont have older populations and smaller procedure bases, with demand concentrated in regional centers and cross-state referral pathways.

The Northeast is a high-value market per case because procedure complexity, physician specialization, and technology intensity are above the national average. It is also one of the most demanding procurement environments. Hospitals expect randomized evidence, real-world outcomes, cybersecurity review for connected systems, and clear economic justification. Mature vendor relationships and group purchasing agreements can create barriers to entry, but successful adoption at a leading Northeast center can influence national practice and fellowship training.

Growth is expected to remain below the West and South because population expansion is slower and the market is already highly penetrated. Revenue will nevertheless rise through greater use of intravascular imaging, drug-coated balloons, advanced lesion preparation, and high-risk PCI support. The region will remain strategically important for evidence generation and premium technology adoption.

Midwest

The Midwest was valued at approximately USD 1.03 billion in 2025 and is forecast to reach about USD 2.15 billion by 2035, representing a CAGR of approximately 7.64%. The region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota. It combines large metropolitan cardiac programs with extensive community and rural referral networks. The market is supported by high chronic disease prevalence in several states, a mature installed base of cath labs, and strong cardiovascular device expertise.

Illinois, Ohio, Michigan, and Minnesota are the leading state markets. Chicago supports a broad academic and community hospital ecosystem with strong demand across routine, acute, and complex PCI. Ohio has major cardiovascular referral centers and a large population with substantial coronary disease burden. Michigan supports high volumes of coronary intervention and heart failure care. Minnesota is strategically important because of its medtech cluster, clinical expertise, and close interaction between device development and provider adoption.

Indiana, Wisconsin, and Missouri offer stable demand through large health systems and regional STEMI networks. These states are attractive for vendors that can support enterprise contracts, clinical education, and dependable field service. Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller absolute markets but rely heavily on regional centers for advanced PCI. Rural transfer distance makes rapid access to primary PCI a continuing challenge, increasing the importance of hub-and-spoke planning, inventory reliability, and systems that minimize complication risk.

The Midwest is typically more price-sensitive than coastal academic markets, but it is receptive to technology that produces operational savings or enables a service line to retain complex referrals. Imaging and calcium modification adoption will expand, though hospital capital cycles and staffing constraints may slow diffusion. Vendor success depends on clinical training, supply assurance, and the ability to demonstrate value in both high-volume urban centers and smaller affiliated hospitals.

The region is not expected to outgrow the South or West, yet it will remain a durable revenue base. Growth will be driven by replacement of aging cath lab systems, increasing radial access, expansion of CHIP programs, and wider use of imaging-guided PCI. Minnesota, Illinois, Ohio, Michigan, Wisconsin, Indiana, and Missouri will account for the majority of regional revenue, while rural states will create targeted opportunities for streamlined and remotely supported technology.

Key Market Players

The U.S. Percutaneous Coronary Intervention Devices Competitive Landscape is moderately consolidated in drug-eluting stents, intravascular imaging, physiology, calcium modification, and mechanical circulatory support, while guidewires, catheters, specialty balloons, closure devices, and contract manufacturing remain more fragmented. Competitive advantage is increasingly platform-based. Manufacturers seek to control multiple steps of the PCI workflow so that imaging or physiology pulls through lesion preparation, stents, balloons, and support products. Hospital contracting, physician training, clinical evidence, supply reliability, and reimbursement support are as important as device performance.

Large companies can offer national service coverage, capital placement, consignment inventory, and enterprise rebates. Specialized companies compete through superior crossability, lesion-specific performance, unique imaging, or focused innovation in CTO, calcium, thrombus, and high-risk PCI. Consolidation is expected to continue because high-growth categories such as intravascular lithotripsy and AI-enabled coronary guidance are strategically valuable to companies with established cath lab sales channels.

Some of the key players in the U.S. Percutaneous Coronary Intervention Devices industry are

Abbott Laboratories,
Boston Scientific Corporation,
Medtronic,
Johnson & Johnson MedTech,
Shockwave Medical,
Abiomed,
Terumo Medical Corporation,
Philips,
GE HealthCare,
Siemens Healthineers,
Teleflex,
Cordis,
BIOTRONIK,
B. Braun Medical,
Merit Medical Systems,
Asahi Intecc,
Nipro Medical Corporation,
Infraredx,
ACIST Medical Systems,
Getinge,
Penumbra,
Canon Medical Systems USA,
Elixir Medical,
Integer Holdings.

Abbott, Boston Scientific, Medtronic, Johnson & Johnson MedTech, Terumo, and Philips hold the strongest positions across major coronary product categories. Abbott combines drug-eluting stents, balloons, vascular access, closure, and orbital atherectomy. Boston Scientific competes in stents, balloons, IVUS, rotational atherectomy, and emerging lithotripsy. Johnson & Johnson has built a high-growth cardiovascular platform around Shockwave IVL and Abiomed circulatory support. Philips is influential in cath lab imaging, IVUS, iFR, co-registration, and connected procedural workflow. Terumo and Asahi Intecc are particularly important in guidewires, access, and complex PCI tools.

Future share gains will depend on evidence in complex lesions, drug-coated balloon adoption, imaging workflow simplification, next-generation IVL, lower-profile circulatory support, and digital integration. Companies that can demonstrate fewer complications, lower contrast use, shorter procedure time, improved stent expansion, and reduced repeat revascularization will be best positioned to defend premium pricing. The ability to maintain inventory during supply disruption and provide experienced clinical specialists will remain a major differentiator in U.S. cath labs.

Recent Developments

In February 2024, the FDA approved the first coronary drug-coated balloon in the United States for treatment of in-stent restenosis after appropriate vessel preparation. The approval created a new “leave nothing behind” option for selected patients and opened a commercial category that had already been established in other markets. U.S. adoption is expected to be protocol-driven because lesion preparation, imaging, residual stenosis, and dissection management determine treatment success.

In May 2024, Johnson & Johnson completed its approximately USD 13.1 billion acquisition of Shockwave Medical. The transaction placed coronary intravascular lithotripsy within a broad global medtech organization and confirmed the strategic value of calcium modification. The acquisition also intensified competitive investment in alternative lithotripsy platforms, atherectomy, and integrated vessel preparation.

During 2024 and 2025, the U.S. clinical environment moved more strongly toward imaging-guided PCI. The 2025 acute coronary syndromes guideline made intravascular imaging a top-level recommendation for complex coronary lesions and continued to prefer radial over femoral access. This change is expected to influence capital purchasing, physician training, and hospital quality protocols over several years rather than produce an immediate one-time shift.

In 2025, Boston Scientific announced an agreement to acquire the remaining interest in Bolt Medical, developer of an investigational laser-based IVL platform. The coronary system entered a U.S. investigational pathway for severely calcified lesions. Although commercialization is dependent on regulatory and clinical milestones, the transaction illustrates the emergence of a second innovation cycle in lithotripsy and the willingness of large PCI companies to invest before approval.

AI-enabled coronary guidance also advanced. Angiography-derived FFR, automated IVUS measurements, co-registration, and image-based treatment planning are moving from isolated software tools toward integrated cath lab platforms. New clinical evidence presented in 2025 supported the potential of AI-powered angiographic physiology to guide revascularization decisions. Commercial adoption will depend on interoperability, data security, reimbursement, and the ability to improve workflow without increasing procedure time.

Outpatient PCI continued to expand selectively, supported by radial access, same-day discharge, and Medicare coverage of designated procedures in ASCs. The absolute ASC share remains small, indicating that hospitals will retain the majority of PCI volume. Nevertheless, the shift is strategically important because it changes purchasing criteria toward compact systems, standardized disposables, lower recovery burden, and transparent case economics.

Conclusion

The U.S. Percutaneous Coronary Intervention Devices Market Size & Share is positioned to expand from USD 5.35 billion in 2025 to USD 11.71 billion by 2035, supported by an 8.15% CAGR during the forecast period. The market is clinically essential, procedure-driven, and increasingly differentiated by the complexity of treated disease rather than by basic PCI volume alone. Coronary stents will remain the largest established product category, but the fastest value creation will occur in intravascular imaging, physiology, drug-coated balloons, calcium modification, specialty delivery systems, and high-risk PCI support.

The most important strategic change is the transition from angiography-only intervention to precision PCI. The combination of radial access, imaging, physiology, structured lesion preparation, and post-deployment confirmation can improve outcomes and make procedure economics more predictable. Hospitals will increasingly favor vendors that reduce variability across operators and facilities, support same-day discharge where appropriate, and provide evidence for total episode value. This creates an advantage for integrated platforms but preserves room for specialist innovators that solve difficult problems in CTO, calcification, restenosis, thrombus, or hemodynamic instability.

Regional opportunity will be led by the South because of population scale, disease burden, and hospital expansion. The West will grow fastest due to demographic expansion and early adoption of digital and image-guided technology. The Northeast will remain a high-value evidence and training market, while the Midwest will provide stable demand supported by established cardiac networks and medtech expertise. Texas, Florida, California, New York, Pennsylvania, Illinois, Ohio, New Jersey, North Carolina, Georgia, Arizona, Michigan, Massachusetts, Tennessee, and Minnesota will be especially important commercial states.

For clients evaluating this market, the central questions are where device intensity per procedure will increase, how imaging and physiology will change implant and lesion-preparation choices, which technologies will receive reimbursement and guideline support, and how site-of-care migration will affect pricing. Companies that combine clinical differentiation, workflow integration, economic evidence, regulatory execution, and dependable cath lab support will define the competitive landscape through 2035.

TABLE OF CONTENT

1. U.S. Percutaneous Coronary Intervention Devices Market: Market Introduction & Context
1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. PCI Device Manufacturers and Technology Developers
1.6.2. Cath Lab Imaging, Physiology, and Capital Equipment Suppliers
1.6.3. Component Suppliers and Contract Manufacturing Organizations
1.6.4. Hospitals, Integrated Delivery Networks, and Cardiac Service Lines
1.6.5. Academic, Tertiary, and Complex PCI Referral Centers
1.6.6. Community Hospitals, Outpatient Departments, and Ambulatory Surgery Centers
1.6.7. Group Purchasing Organizations, Distributors, and Specialty Suppliers
1.6.8. Payers, Regulators, Clinical Societies, and Value Analysis Committees
What this section provides: This section defines the PCI device market boundary, study scope, research methodology, assumptions, and stakeholder ecosystem so clients understand how the U.S. market is measured, segmented, and validated.

2. U.S. Percutaneous Coronary Intervention Devices Market: Executive Summary
2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.7.1. Imaging-Guided and Physiology-Guided PCI
2.7.2. Coronary Drug-Coated Balloons
2.7.3. Intravascular Lithotripsy and Calcium Modification
2.7.4. Complex and High-Risk Indicated PCI
2.7.5. Radial-First and Same-Day Discharge Pathways
What this section provides: This section gives decision-makers a concise view of market size, growth direction, device-intensity trends, competitive pressure, procedural shifts, and the most attractive PCI opportunity areas through 2035.

3. U.S. Percutaneous Coronary Intervention Devices Market: Market Dynamics & Outlook
3.1. Drivers and Their Impact Analysis
3.1.1. Persistent U.S. Coronary Artery Disease and Acute Coronary Syndrome Burden
3.1.2. Aging, Diabetes, Chronic Kidney Disease, and Calcified Coronary Anatomy
3.1.3. Expansion of Minimally Invasive Coronary Revascularization
3.1.4. Adoption of Intravascular Imaging and Coronary Physiology
3.1.5. Growth of Complex and High-Risk Indicated PCI Programs
3.1.6. Radial Access, Same-Day Discharge, and Outpatient PCI Migration
3.2. Restraints and Their Impact Analysis
3.2.1. Price Erosion in Mature Coronary Stent and Balloon Categories
3.2.2. Reimbursement Packaging and Hospital Value Analysis Scrutiny
3.2.3. Appropriateness Review and Competition from Guideline-Directed Medical Therapy
3.2.4. Product Recall, Thrombosis, Bleeding, Perforation, and Access-Site Risk
3.2.5. Interventional Cardiology Workforce and Rural Cath Lab Access Constraints
3.3. Opportunities and Their Impact Analysis
3.3.1. Coronary Drug-Coated Balloon Adoption for In-Stent Restenosis
3.3.2. Intravascular Lithotripsy, Atherectomy, and Structured Calcium Modification
3.3.3. IVUS, OCT, FFR, iFR, and Angiography-Derived Physiology
3.3.4. CTO, Left Main, Multivessel, and Protected High-Risk PCI
3.3.5. AI-Assisted Coronary Guidance and Robotic PCI
3.3.6. Ambulatory Surgery Center and Specialized Outpatient Cath Lab Expansion
3.4. Challenges and Their Impact Analysis
3.4.1. Clinical Evidence Translation into Routine Community Practice
3.4.2. Capital Budget Competition and Console Standardization
3.4.3. Physician Preference Variation and Inventory Complexity
3.4.4. Cybersecurity, Interoperability, and Digital Workflow Integration
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement Behavior Analysis
3.8. Cath Lab Throughput, Length of Stay, and Total Episode Cost Analysis
What this section provides: This section explains the clinical, commercial, reimbursement, operational, and procurement forces shaping U.S. PCI device demand, enabling clients to assess growth potential, adoption barriers, and execution risk.

4. U.S. Percutaneous Coronary Intervention Devices Market: Market Environment & Industry Analysis
4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Hospital and IDN Buyers
4.2.3. Bargaining Power of Component and Contract Manufacturing Suppliers
4.2.4. Substitution Risk from Medical Therapy and Coronary Artery Bypass Grafting
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization, AI, and Connected Cath Lab Workflows
4.6. Clinical Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.8. CMS Reimbursement, Coverage, and Coding Landscape
4.8.1. Inpatient Prospective Payment System Considerations
4.8.2. Hospital Outpatient Prospective Payment System Considerations
4.8.3. Ambulatory Surgical Center Payment Considerations
4.8.4. Transitional and New Technology Payment Considerations
4.9. Import/Export Restrictions, Tariffs, and Component Sourcing Impact
4.10. Government Initiatives, STEMI Networks, and Cardiovascular Quality Programs
4.11. Impact of Escalating Geopolitical Tensions
4.12. Hospital Value Analysis Committee Decision Framework
4.13. Physician Preference Item and Vendor Standardization Analysis
What this section provides: This section gives clients a complete view of regulation, reimbursement, pricing, supply chain, technology adoption, competitive forces, and hospital purchasing criteria affecting PCI devices in the United States.

5. U.S. Percutaneous Coronary Intervention Devices Market – By Product Category
5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Coronary Stents and Scaffolds
5.1.2.1. Drug-Eluting Stents
5.1.2.2. Bare-Metal Stents
5.1.2.3. Covered Coronary Stents
5.1.2.4. Bioresorbable Coronary Scaffolds
5.1.3. Balloon Catheters
5.1.3.1. Semi-Compliant PTCA Balloons
5.1.3.2. Non-Compliant and Ultra-High-Pressure Balloons
5.1.3.3. Scoring and Cutting Balloons
5.1.3.4. Coronary Drug-Coated Balloons
5.1.3.5. Perfusion and Specialty Balloons
5.1.4. Guidewires, Catheters, and Access Devices
5.1.4.1. Workhorse Coronary Guidewires
5.1.4.2. Specialty and Chronic Total Occlusion Guidewires
5.1.4.3. Guiding Catheters, Introducer Sheaths, and Access Kits
5.1.4.4. Microcatheters and Dual-Lumen Catheters
5.1.4.5. Guide Extension and Support Catheters
5.1.5. Plaque Modification and Thrombus Management Devices
5.1.5.1. Rotational Atherectomy Systems
5.1.5.2. Orbital Atherectomy Systems
5.1.5.3. Coronary Intravascular Lithotripsy Systems
5.1.5.4. Excimer Laser Coronary Atherectomy Systems
5.1.5.5. Aspiration Thrombectomy and Embolic Protection Devices
5.1.6. Intravascular Imaging and Coronary Physiology Devices
5.1.6.1. Intravascular Ultrasound Catheters and Consoles
5.1.6.2. Optical Coherence Tomography Catheters and Consoles
5.1.6.3. Pressure Wires and Wire-Based FFR/iFR Systems
5.1.6.4. Angiography-Derived Physiology Platforms
5.1.6.5. Co-Registration, Measurement, and Guidance Software
5.1.7. Vascular Closure and Hemodynamic Support Devices
5.1.7.1. Radial Compression Devices
5.1.7.2. Femoral Vascular Closure Devices
5.1.7.3. Percutaneous Ventricular Assist Devices
5.1.7.4. Intra-Aortic Balloon Pumps
5.1.7.5. Large-Bore Access and Closure Systems
What this section provides: This section identifies the PCI product categories and subcategories expected to contribute the greatest revenue, device intensity, clinical differentiation, and growth through 2035.

6. U.S. Percutaneous Coronary Intervention Devices Market – By Clinical Application
6.1. Overview
6.1.1. Segment Share Analysis, By Clinical Application, 2025 & 2035 (%)
6.1.2. ST-Elevation Myocardial Infarction PCI
6.1.3. Non-ST-Elevation Acute Coronary Syndrome and Unstable Angina
6.1.4. Stable Ischemic Heart Disease and Elective PCI
6.1.5. Complex and High-Risk Indicated PCI
6.1.5.1. Left Main Coronary Intervention
6.1.5.2. Multivessel and Bifurcation PCI
6.1.5.3. Chronic Total Occlusion PCI
6.1.5.4. Severely Calcified Coronary Lesions
6.1.5.5. Prior CABG, Saphenous Vein Graft, and Surgical Turn-Down Cases
6.1.5.6. Low Ejection Fraction and Protected High-Risk PCI
6.1.6. In-Stent Restenosis and Stent Failure
6.1.6.1. Stent Underexpansion
6.1.6.2. Neoatherosclerosis and Recurrent Restenosis
6.1.6.3. Stent Fracture, Edge Disease, and Multiple Metal Layers
What this section provides: This section evaluates PCI device demand by clinical presentation and lesion complexity, helping clients identify applications with the strongest procedure growth, adjunct-device use, reimbursement relevance, and unmet clinical need.

7. U.S. Percutaneous Coronary Intervention Devices Market – By Technology & Procedural Guidance
7.1. Overview
7.1.1. Segment Share Analysis, By Technology & Procedural Guidance, 2025 & 2035 (%)
7.1.2. Angiography-Guided Conventional PCI
7.1.3. Intravascular Imaging-Guided PCI
7.1.3.1. IVUS-Guided PCI
7.1.3.2. OCT-Guided PCI
7.1.4. Physiology-Guided PCI
7.1.4.1. Wire-Based FFR and Resting Pressure Indices
7.1.4.2. Angiography-Derived FFR and Computational Physiology
7.1.5. Advanced Lesion Preparation and Calcium Modification
7.1.5.1. Atherectomy-Led Strategies
7.1.5.2. Intravascular Lithotripsy-Led Strategies
7.1.5.3. Combined and Imaging-Directed Calcium Algorithms
7.1.6. AI-Enabled, Robotic, and Digitally Integrated PCI
7.1.6.1. AI-Assisted Angiography and Image Interpretation
7.1.6.2. Automated IVUS/OCT Measurement and Co-Registration
7.1.6.3. Robotic PCI and Radiation-Reduction Platforms
7.1.6.4. CT-to-Cath Lab Planning and Digital Documentation
What this section provides: This section evaluates the procedural guidance and technology platforms reshaping coronary intervention, including imaging, physiology, lesion preparation, AI, robotics, and digitally integrated cath lab workflows.

8. U.S. Percutaneous Coronary Intervention Devices Market – By End User
8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Large Hospitals and Integrated Delivery Networks
8.1.3. Academic and Tertiary Heart Centers
8.1.4. Community Hospitals and Regional STEMI Centers
8.1.5. Hospital Outpatient Departments
8.1.6. Ambulatory Surgery Centers and Specialized Outpatient Cath Labs
What this section provides: This section explains which provider settings drive PCI device purchasing and adoption, highlighting differences in case complexity, capital capacity, vendor standardization, throughput priorities, and outpatient economics.

9. U.S. Percutaneous Coronary Intervention Devices Market – By Procurement Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Hospital and Health System Procurement
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.4. Group Purchasing Organization Contracts
9.1.5. Capital Placement, Consumables Commitment, and Managed Service Agreements
9.1.6. Distributor and Specialty Supplier Sales
9.1.7. Ambulatory Surgery Center and Independent Cath Lab Procurement
9.1.8. Consignment Inventory and Physician Preference Item Contracting
What this section provides: This section clarifies how PCI devices are purchased in the United States, including enterprise contracting, GPO influence, capital-console placement, consignment models, distributor roles, and outpatient procurement behavior.

10. U.S. Percutaneous Coronary Intervention Devices Market – By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional PCI Procedure Volume and Cath Lab Infrastructure Analysis
10.1.4. Regional Coronary Disease Burden and Patient Demographic Analysis
10.1.5. Regional Reimbursement, Site-of-Care, and Procurement Dynamics
10.1.6. Regional Imaging, Physiology, and Complex PCI Adoption Analysis
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region PCI Device Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region PCI Device Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region PCI Device Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region PCI Device Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology & Procedural Guidance, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
What this section provides: This section provides detailed regional and state-level analysis across all 50 states, helping clients identify PCI procedure hubs, disease-burden markets, imaging and calcium-modification adoption hotspots, cath lab capacity, site-of-care shifts, and commercial opportunities.

11. U.S. Percutaneous Coronary Intervention Devices Market: Competitive Landscape & Company Profiles
11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Company Profiles
11.3.1. Abbott Laboratories
11.3.2. Boston Scientific Corporation
11.3.3. Medtronic
11.3.4. Johnson & Johnson MedTech
11.3.5. Shockwave Medical
11.3.6. Abiomed
11.3.7. Terumo Medical Corporation
11.3.8. Philips
11.3.9. GE HealthCare
11.3.10. Siemens Healthineers
11.3.11. Teleflex
11.3.12. Cordis
11.3.13. BIOTRONIK
11.3.14. B. Braun Medical
11.3.15. Merit Medical Systems
11.3.16. Asahi Intecc
11.3.17. Nipro Medical Corporation
11.3.18. Infraredx
11.3.19. ACIST Medical Systems
11.3.20. Getinge
11.3.21. Penumbra
11.3.22. Canon Medical Systems USA
11.3.23. Elixir Medical
11.3.24. Integer Holdings
Note: Each company profile will include company overview, PCI device portfolio, U.S. commercial strategy, financial positioning, cath lab platform integration, clinical evidence, regulatory updates, partnerships, acquisitions, and recent developments.
What this section provides: This section gives clients competitor benchmarking, market share visibility, portfolio positioning, technology differentiation, channel strength, clinical evidence direction, and strategic intelligence on leading PCI device companies.

12. U.S. Percutaneous Coronary Intervention Devices Market: Future Market Outlook, 2026–2035
12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Coronary Drug-Coated Balloons and Leave-Nothing-Behind Strategies
12.2.2. Next-Generation Intravascular Lithotripsy and Calcium Modification
12.2.3. AI-Enhanced IVUS, OCT, and Angiography-Derived Physiology
12.2.4. Robotic PCI, Remote Support, and Radiation-Reduction Technologies
12.2.5. Bioresorbable Scaffolds and Next-Generation Coronary Implants
12.2.6. High-Risk PCI Support and Large-Bore Closure Innovation
12.3. Emerging Business Trends
12.3.1. Platform Bundling Across Imaging, Physiology, Lesion Preparation, and Implants
12.3.2. Enterprise Cath Lab Standardization and Vendor Consolidation
12.3.3. Outpatient PCI and Same-Day Discharge Expansion
12.3.4. Outcomes-Based Procurement and Real-World Evidence Requirements
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
What this section provides: This section prepares clients for future technology shifts, market structure changes, investment opportunities, reimbursement evolution, and plausible PCI adoption scenarios through 2035.

13. U.S. Percutaneous Coronary Intervention Devices Market: Strategic Recommendations
13.1. Recommendations for PCI Device Manufacturers
13.2. Recommendations for Hospitals, IDNs, and Cardiac Service Lines
13.3. Recommendations for Investors and Private Equity Firms
13.4. Recommendations for Distributors and Channel Partners
13.5. Recommendations for New Entrants and Startups
13.6. U.S. Go-to-Market Strategy Considerations
13.7. Product Positioning and Portfolio Expansion Guidance
13.8. Clinical Evidence, Reimbursement, and Physician Training Strategy
13.9. State and Regional Commercial Prioritization Framework
What this section provides: This section converts market intelligence into actionable strategy for product development, portfolio expansion, clinical evidence planning, market access, channel design, hospital contracting, geographic prioritization, and competitive differentiation.

14. U.S. Percutaneous Coronary Intervention Devices Market: Disclaimer
14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
What this section provides: This section clarifies the report’s scope limitations, legal boundaries, data-use terms, third-party information treatment, and forecasting assumptions.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Percutaneous Coronary Intervention Devices Market: Market Definition and Scope
TABLE 3: U.S. Percutaneous Coronary Intervention Devices Market: Research Methodology Framework
TABLE 4: U.S. Percutaneous Coronary Intervention Devices Market: Key Assumptions
TABLE 5: U.S. Percutaneous Coronary Intervention Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Percutaneous Coronary Intervention Devices Market: Stakeholder Analysis
TABLE 7: U.S. Percutaneous Coronary Intervention Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Percutaneous Coronary Intervention Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Percutaneous Coronary Intervention Devices Market: Market Attractiveness Index
TABLE 10: U.S. Percutaneous Coronary Intervention Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Percutaneous Coronary Intervention Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Percutaneous Coronary Intervention Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Percutaneous Coronary Intervention Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Percutaneous Coronary Intervention Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Percutaneous Coronary Intervention Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Percutaneous Coronary Intervention Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Percutaneous Coronary Intervention Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Percutaneous Coronary Intervention Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Percutaneous Coronary Intervention Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Percutaneous Coronary Intervention Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Percutaneous Coronary Intervention Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 22: U.S. Percutaneous Coronary Intervention Devices Market: Cath Lab Throughput, Length of Stay and Total Episode Cost Analysis
TABLE 23: U.S. Percutaneous Coronary Intervention Devices Market: PESTEL Analysis
TABLE 24: U.S. Percutaneous Coronary Intervention Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Percutaneous Coronary Intervention Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Percutaneous Coronary Intervention Devices Market: Value Chain Analysis
TABLE 27: U.S. Percutaneous Coronary Intervention Devices Market: Supply Chain Analysis
TABLE 28: U.S. Percutaneous Coronary Intervention Devices Market: Digitalization, AI and Connected Cath Lab Workflow Impact
TABLE 29: U.S. Percutaneous Coronary Intervention Devices Market: Clinical Application & Innovation Landscape
TABLE 30: U.S. Percutaneous Coronary Intervention Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Percutaneous Coronary Intervention Devices Market: CMS Reimbursement, Coverage and Coding Landscape
TABLE 32: U.S. Percutaneous Coronary Intervention Devices Market: Inpatient Prospective Payment System Considerations
TABLE 33: U.S. Percutaneous Coronary Intervention Devices Market: Hospital Outpatient Prospective Payment System Considerations
TABLE 34: U.S. Percutaneous Coronary Intervention Devices Market: Ambulatory Surgical Center Payment Considerations
TABLE 35: U.S. Percutaneous Coronary Intervention Devices Market: Transitional and New Technology Payment Considerations
TABLE 36: U.S. Percutaneous Coronary Intervention Devices Market: Import/Export Restrictions, Tariffs and Component Sourcing Impact
TABLE 37: U.S. Percutaneous Coronary Intervention Devices Market: Government Initiatives, STEMI Networks and Cardiovascular Quality Programs
TABLE 38: U.S. Percutaneous Coronary Intervention Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 39: U.S. Percutaneous Coronary Intervention Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 40: U.S. Percutaneous Coronary Intervention Devices Market: Physician Preference Item and Vendor Standardization Analysis
TABLE 41: U.S. Percutaneous Coronary Intervention Devices Market: Product Category Snapshot, 2025
TABLE 42: Segment Dashboard; Definition and Scope, by Product Category
TABLE 43: U.S. Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 44: U.S. Percutaneous Coronary Intervention Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 45: U.S. Percutaneous Coronary Intervention Devices Market: Coronary Stents and Scaffolds Market Size and Forecast, by Subcategory, 2021–2035 (US$ Billion)
TABLE 46: U.S. Percutaneous Coronary Intervention Devices Market: Balloon Catheters Market Size and Forecast, by Subcategory, 2021–2035 (US$ Billion)
TABLE 47: U.S. Percutaneous Coronary Intervention Devices Market: Guidewires, Catheters and Access Devices Market Size and Forecast, by Subcategory, 2021–2035 (US$ Billion)
TABLE 48: U.S. Percutaneous Coronary Intervention Devices Market: Plaque Modification and Thrombus Management Devices Market Size and Forecast, by Subcategory, 2021–2035 (US$ Billion)
TABLE 49: U.S. Percutaneous Coronary Intervention Devices Market: Intravascular Imaging and Coronary Physiology Devices Market Size and Forecast, by Subcategory, 2021–2035 (US$ Billion)
TABLE 50: U.S. Percutaneous Coronary Intervention Devices Market: Vascular Closure and Hemodynamic Support Devices Market Size and Forecast, by Subcategory, 2021–2035 (US$ Billion)
TABLE 51: U.S. Percutaneous Coronary Intervention Devices Market: Clinical Application Snapshot, 2025
TABLE 52: Segment Dashboard; Definition and Scope, by Clinical Application
TABLE 53: U.S. Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 54: U.S. Percutaneous Coronary Intervention Devices Market: Segment Share Analysis, by Clinical Application, 2025 & 2035 (%)
TABLE 55: U.S. Percutaneous Coronary Intervention Devices Market: ST-Elevation Myocardial Infarction PCI Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Percutaneous Coronary Intervention Devices Market: Non-ST-Elevation Acute Coronary Syndrome and Unstable Angina Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Percutaneous Coronary Intervention Devices Market: Stable Ischemic Heart Disease and Elective PCI Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Percutaneous Coronary Intervention Devices Market: Complex and High-Risk Indicated PCI Market Size and Forecast, by Subcategory, 2021–2035 (US$ Billion)
TABLE 59: U.S. Percutaneous Coronary Intervention Devices Market: In-Stent Restenosis and Stent Failure Market Size and Forecast, by Subcategory, 2021–2035 (US$ Billion)
TABLE 60: U.S. Percutaneous Coronary Intervention Devices Market: Technology & Procedural Guidance Snapshot, 2025
TABLE 61: Segment Dashboard; Definition and Scope, by Technology & Procedural Guidance
TABLE 62: U.S. Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 63: U.S. Percutaneous Coronary Intervention Devices Market: Segment Share Analysis, by Technology & Procedural Guidance, 2025 & 2035 (%)
TABLE 64: U.S. Percutaneous Coronary Intervention Devices Market: Angiography-Guided Conventional PCI Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Percutaneous Coronary Intervention Devices Market: Intravascular Imaging-Guided PCI Market Size and Forecast, by Modality, 2021–2035 (US$ Billion)
TABLE 66: U.S. Percutaneous Coronary Intervention Devices Market: Physiology-Guided PCI Market Size and Forecast, by Modality, 2021–2035 (US$ Billion)
TABLE 67: U.S. Percutaneous Coronary Intervention Devices Market: Advanced Lesion Preparation and Calcium Modification Market Size and Forecast, by Strategy, 2021–2035 (US$ Billion)
TABLE 68: U.S. Percutaneous Coronary Intervention Devices Market: AI-Enabled, Robotic and Digitally Integrated PCI Market Size and Forecast, by Technology, 2021–2035 (US$ Billion)
TABLE 69: U.S. Percutaneous Coronary Intervention Devices Market: End User Snapshot, 2025
TABLE 70: Segment Dashboard; Definition and Scope, by End User
TABLE 71: U.S. Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 72: U.S. Percutaneous Coronary Intervention Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 73: U.S. Percutaneous Coronary Intervention Devices Market: Large Hospitals and Integrated Delivery Networks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Percutaneous Coronary Intervention Devices Market: Academic and Tertiary Heart Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Percutaneous Coronary Intervention Devices Market: Community Hospitals and Regional STEMI Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Percutaneous Coronary Intervention Devices Market: Hospital Outpatient Departments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Percutaneous Coronary Intervention Devices Market: Ambulatory Surgery Centers and Specialized Outpatient Cath Labs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Percutaneous Coronary Intervention Devices Market: Procurement Channel Snapshot, 2025
TABLE 79: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 80: U.S. Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 81: U.S. Percutaneous Coronary Intervention Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 82: U.S. Percutaneous Coronary Intervention Devices Market: Direct Hospital and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Percutaneous Coronary Intervention Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Percutaneous Coronary Intervention Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. Percutaneous Coronary Intervention Devices Market: Capital Placement, Consumables Commitment and Managed Service Agreements Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. Percutaneous Coronary Intervention Devices Market: Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: U.S. Percutaneous Coronary Intervention Devices Market: Ambulatory Surgery Center and Independent Cath Lab Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: U.S. Percutaneous Coronary Intervention Devices Market: Consignment Inventory and Physician Preference Item Contracting Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: U.S. Percutaneous Coronary Intervention Devices Market: Regional Snapshot, 2025
TABLE 90: Segment Dashboard; Definition and Scope, by Region
TABLE 91: U.S. Percutaneous Coronary Intervention Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 92: U.S. Percutaneous Coronary Intervention Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 93: West Region U.S. Percutaneous Coronary Intervention Devices Market: Regional Overview and Trends
TABLE 94: West Region U.S. Percutaneous Coronary Intervention Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 95: West Region U.S. Percutaneous Coronary Intervention Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 96: West Region U.S. Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 98: West Region U.S. Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 99: West Region U.S. Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 100: West Region U.S. Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 101: California Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 102: California Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 103: California Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 104: California Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 105: California Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 106: Washington Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 107: Washington Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 108: Washington Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 109: Washington Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 110: Washington Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 111: Arizona Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 112: Arizona Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 113: Arizona Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 114: Arizona Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 115: Arizona Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 116: Colorado Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 117: Colorado Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 118: Colorado Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 119: Colorado Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 120: Colorado Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 121: Oregon Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 122: Oregon Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 123: Oregon Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 124: Oregon Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 125: Oregon Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 126: Utah Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 127: Utah Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 128: Utah Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 129: Utah Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 130: Utah Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 131: Nevada Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 132: Nevada Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 133: Nevada Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 134: Nevada Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 135: Nevada Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 136: New Mexico Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 137: New Mexico Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 138: New Mexico Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 139: New Mexico Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 140: New Mexico Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 141: Idaho Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 142: Idaho Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 143: Idaho Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 144: Idaho Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 145: Idaho Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 146: Montana Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 147: Montana Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 148: Montana Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 149: Montana Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 150: Montana Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 151: Wyoming Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 152: Wyoming Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 153: Wyoming Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 154: Wyoming Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 155: Wyoming Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 156: Alaska Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 157: Alaska Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 158: Alaska Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 159: Alaska Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 160: Alaska Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 161: Hawaii Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 162: Hawaii Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 163: Hawaii Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 164: Hawaii Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 165: Hawaii Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 166: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market: Regional Overview and Trends
TABLE 167: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 168: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 169: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 170: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 171: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 172: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 173: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 174: New York Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 175: New York Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 176: New York Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 177: New York Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 178: New York Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 179: Massachusetts Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 180: Massachusetts Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 181: Massachusetts Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 182: Massachusetts Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 183: Massachusetts Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 184: New Jersey Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 185: New Jersey Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 186: New Jersey Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 187: New Jersey Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 188: New Jersey Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 189: Pennsylvania Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 190: Pennsylvania Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 191: Pennsylvania Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 192: Pennsylvania Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 193: Pennsylvania Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 194: Connecticut Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 195: Connecticut Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 196: Connecticut Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 197: Connecticut Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 198: Connecticut Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 199: Maine Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 200: Maine Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 201: Maine Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 202: Maine Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 203: Maine Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 204: Vermont Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 205: Vermont Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 206: Vermont Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 207: Vermont Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 208: Vermont Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 209: New Hampshire Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 210: New Hampshire Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 211: New Hampshire Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 212: New Hampshire Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 213: New Hampshire Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 214: Rhode Island Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 215: Rhode Island Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 216: Rhode Island Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 217: Rhode Island Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 218: Rhode Island Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 219: Delaware Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 220: Delaware Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 221: Delaware Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 222: Delaware Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 223: Delaware Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 224: South Region U.S. Percutaneous Coronary Intervention Devices Market: Regional Overview and Trends
TABLE 225: South Region U.S. Percutaneous Coronary Intervention Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 226: South Region U.S. Percutaneous Coronary Intervention Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 227: South Region U.S. Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 228: South Region U.S. Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 229: South Region U.S. Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 230: South Region U.S. Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 231: South Region U.S. Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 232: Texas Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 233: Texas Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 234: Texas Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 235: Texas Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 236: Texas Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 237: Florida Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 238: Florida Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 239: Florida Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 240: Florida Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 241: Florida Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 242: Georgia Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 243: Georgia Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 244: Georgia Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 245: Georgia Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 246: Georgia Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 247: North Carolina Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 248: North Carolina Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 249: North Carolina Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 250: North Carolina Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 251: North Carolina Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 252: Tennessee Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 253: Tennessee Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 254: Tennessee Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 255: Tennessee Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 256: Tennessee Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 257: South Carolina Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 258: South Carolina Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 259: South Carolina Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 260: South Carolina Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 261: South Carolina Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 262: Alabama Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 263: Alabama Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 264: Alabama Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 265: Alabama Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 266: Alabama Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 267: Mississippi Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 268: Mississippi Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 269: Mississippi Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 270: Mississippi Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 271: Mississippi Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 272: Louisiana Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 273: Louisiana Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 274: Louisiana Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 275: Louisiana Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 276: Louisiana Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 277: Arkansas Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 278: Arkansas Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 279: Arkansas Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 280: Arkansas Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 281: Arkansas Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 282: Kentucky Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 283: Kentucky Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 284: Kentucky Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 285: Kentucky Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 286: Kentucky Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 287: Oklahoma Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 288: Oklahoma Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 289: Oklahoma Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 290: Oklahoma Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 291: Oklahoma Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 292: Virginia Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 293: Virginia Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 294: Virginia Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 295: Virginia Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 296: Virginia Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 297: Maryland Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 298: Maryland Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 299: Maryland Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 300: Maryland Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 301: Maryland Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 302: West Virginia Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 303: West Virginia Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 304: West Virginia Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 305: West Virginia Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 306: West Virginia Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 307: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market: Regional Overview and Trends
TABLE 308: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 309: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 310: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 311: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 312: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 313: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 314: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 315: Illinois Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 316: Illinois Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 317: Illinois Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 318: Illinois Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 319: Illinois Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 320: Ohio Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 321: Ohio Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 322: Ohio Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 323: Ohio Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 324: Ohio Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 325: Michigan Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 326: Michigan Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 327: Michigan Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 328: Michigan Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 329: Michigan Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 330: Minnesota Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 331: Minnesota Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 332: Minnesota Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 333: Minnesota Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 334: Minnesota Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 335: Indiana Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 336: Indiana Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 337: Indiana Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 338: Indiana Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 339: Indiana Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 340: Wisconsin Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 341: Wisconsin Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 342: Wisconsin Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 343: Wisconsin Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 344: Wisconsin Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 345: Missouri Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 346: Missouri Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 347: Missouri Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 348: Missouri Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 349: Missouri Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 350: Iowa Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 351: Iowa Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 352: Iowa Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 353: Iowa Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 354: Iowa Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 355: Kansas Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 356: Kansas Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 357: Kansas Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 358: Kansas Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 359: Kansas Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 360: Nebraska Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 361: Nebraska Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 362: Nebraska Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 363: Nebraska Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 364: Nebraska Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 365: North Dakota Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 366: North Dakota Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 367: North Dakota Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 368: North Dakota Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 369: North Dakota Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 370: South Dakota Percutaneous Coronary Intervention Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 371: South Dakota Percutaneous Coronary Intervention Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 372: South Dakota Percutaneous Coronary Intervention Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 373: South Dakota Percutaneous Coronary Intervention Devices Market, by Technology & Procedural Guidance, 2021–2035 (US$ Billion)
TABLE 374: South Dakota Percutaneous Coronary Intervention Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 375: U.S. Percutaneous Coronary Intervention Devices Market: Competitive Landscape Snapshot, 2025
TABLE 376: U.S. Percutaneous Coronary Intervention Devices Market: Key Company Market Share Analysis, 2025
TABLE 377: U.S. Percutaneous Coronary Intervention Devices Market: Company Positioning Matrix
TABLE 378: U.S. Percutaneous Coronary Intervention Devices Market: PCI Product and Cath Lab Platform Portfolio Benchmarking of Key Players
TABLE 379: U.S. Percutaneous Coronary Intervention Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 380: Abbott Laboratories: Company Profile
TABLE 381: Boston Scientific Corporation: Company Profile
TABLE 382: Medtronic: Company Profile
TABLE 383: Johnson & Johnson MedTech: Company Profile
TABLE 384: Shockwave Medical: Company Profile
TABLE 385: Abiomed: Company Profile
TABLE 386: Terumo Medical Corporation: Company Profile
TABLE 387: Philips: Company Profile
TABLE 388: GE HealthCare: Company Profile
TABLE 389: Siemens Healthineers: Company Profile
TABLE 390: Teleflex: Company Profile
TABLE 391: Cordis: Company Profile
TABLE 392: BIOTRONIK: Company Profile
TABLE 393: B. Braun Medical: Company Profile
TABLE 394: Merit Medical Systems: Company Profile
TABLE 395: Asahi Intecc: Company Profile
TABLE 396: Nipro Medical Corporation: Company Profile
TABLE 397: Infraredx: Company Profile
TABLE 398: ACIST Medical Systems: Company Profile
TABLE 399: Getinge: Company Profile
TABLE 400: Penumbra: Company Profile
TABLE 401: Canon Medical Systems USA: Company Profile
TABLE 402: Elixir Medical: Company Profile
TABLE 403: Integer Holdings: Company Profile
TABLE 404: U.S. Percutaneous Coronary Intervention Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 405: U.S. Percutaneous Coronary Intervention Devices Market: Disruptive Technologies Impact Matrix
TABLE 406: U.S. Percutaneous Coronary Intervention Devices Market: Emerging Business Trends
TABLE 407: U.S. Percutaneous Coronary Intervention Devices Market: Business Opportunities for Startups and Existing Players
TABLE 408: U.S. Percutaneous Coronary Intervention Devices Market: Investment Prioritization Matrix
TABLE 409: U.S. Percutaneous Coronary Intervention Devices Market: Strategic Recommendations for PCI Device Manufacturers
TABLE 410: U.S. Percutaneous Coronary Intervention Devices Market: Strategic Recommendations for Hospitals, IDNs and Cardiac Service Lines
TABLE 411: U.S. Percutaneous Coronary Intervention Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 412: U.S. Percutaneous Coronary Intervention Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 413: U.S. Percutaneous Coronary Intervention Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 414: U.S. Percutaneous Coronary Intervention Devices Market: U.S. Go-to-Market Strategy Considerations
TABLE 415: U.S. Percutaneous Coronary Intervention Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 416: U.S. Percutaneous Coronary Intervention Devices Market: Clinical Evidence, Reimbursement and Physician Training Strategy
TABLE 417: U.S. Percutaneous Coronary Intervention Devices Market: State and Regional Commercial Prioritization Framework
TABLE 418: U.S. Percutaneous Coronary Intervention Devices Market: Scope Limitation
TABLE 419: U.S. Percutaneous Coronary Intervention Devices Market: Data Use Limitation
TABLE 420: U.S. Percutaneous Coronary Intervention Devices Market: Forecasting Limitation
TABLE 421: U.S. Percutaneous Coronary Intervention Devices Market: Legal Disclaimer
TABLE 422: U.S. Percutaneous Coronary Intervention Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Percutaneous Coronary Intervention Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: PCI Device Market Ecosystem and Stakeholder Map
FIGURE 4: Market Attractiveness Analysis
FIGURE 5: U.S. Percutaneous Coronary Intervention Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Percutaneous Coronary Intervention Devices Market Base Year Market Snapshot, 2025
FIGURE 7: U.S. Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Percutaneous Coronary Intervention Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 9: High-Growth PCI Opportunity Map
FIGURE 10: PCI Device Market Dynamics
FIGURE 11: Market Drivers Impact Matrix
FIGURE 12: Market Restraints and Challenges Matrix
FIGURE 13: PCI Device Opportunity Map
FIGURE 14: PCI Innovation & Patent Landscape, 2021–2025
FIGURE 15: Clinical Workflow Economics Framework
FIGURE 16: Hospital Capital Procurement Decision Framework
FIGURE 17: Cath Lab Throughput, Length of Stay and Total Episode Cost Framework
FIGURE 18: PESTEL Analysis
FIGURE 19: Porter’s Five Forces Analysis
FIGURE 20: Regional PCI Device Pricing Trend, 2025–2035
FIGURE 21: Value Chain Analysis
FIGURE 22: Supply Chain Analysis
FIGURE 23: Digitalization, AI and Connected Cath Lab Workflow Map
FIGURE 24: Clinical Application and PCI Innovation Landscape
FIGURE 25: FDA Regulatory Pathway Framework for PCI Devices
FIGURE 26: CMS Reimbursement, Coverage and Site-of-Care Framework
FIGURE 27: Hospital Value Analysis Committee Decision Framework
FIGURE 28: Physician Preference Item and Vendor Standardization Framework
FIGURE 29: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 30: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Coronary Stents and Scaffolds Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Balloon Catheters Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Guidewires, Catheters and Access Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Plaque Modification and Thrombus Management Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Intravascular Imaging and Coronary Physiology Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Vascular Closure and Hemodynamic Support Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Clinical Application Segment Market Share Analysis, 2025 & 2035
FIGURE 38: Clinical Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: ST-Elevation Myocardial Infarction PCI Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Non-ST-Elevation Acute Coronary Syndrome and Unstable Angina Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Stable Ischemic Heart Disease and Elective PCI Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Complex and High-Risk Indicated PCI Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: In-Stent Restenosis and Stent Failure Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Technology & Procedural Guidance Segment Market Share Analysis, 2025 & 2035
FIGURE 45: Technology & Procedural Guidance Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Angiography-Guided Conventional PCI Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Intravascular Imaging-Guided PCI Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Physiology-Guided PCI Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Advanced Lesion Preparation and Calcium Modification Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: AI-Enabled, Robotic and Digitally Integrated PCI Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 52: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Large Hospitals and Integrated Delivery Networks Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Academic and Tertiary Heart Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Community Hospitals and Regional STEMI Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Hospital Outpatient Departments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Ambulatory Surgery Centers and Specialized Outpatient Cath Labs Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 59: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Direct Hospital and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Capital Placement, Consumables Commitment and Managed Service Agreements Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Ambulatory Surgery Center and Independent Cath Lab Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Consignment Inventory and Physician Preference Item Contracting Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 68: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: West Region U.S. Percutaneous Coronary Intervention Devices Market Share and Leading Players, 2025
FIGURE 70: West Region Market Share Analysis by State, 2025
FIGURE 71: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: California Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Washington Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Arizona Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Colorado Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Oregon Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Utah Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Nevada Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: New Mexico Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Idaho Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Montana Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Wyoming Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Alaska Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Hawaii Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Northeast Region U.S. Percutaneous Coronary Intervention Devices Market Share and Leading Players, 2025
FIGURE 86: Northeast Region Market Share Analysis by State, 2025
FIGURE 87: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: New York Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Massachusetts Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: New Jersey Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Pennsylvania Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Connecticut Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Maine Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Vermont Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: New Hampshire Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Rhode Island Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Delaware Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: South Region U.S. Percutaneous Coronary Intervention Devices Market Share and Leading Players, 2025
FIGURE 99: South Region Market Share Analysis by State, 2025
FIGURE 100: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Texas Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Florida Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Georgia Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: North Carolina Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Tennessee Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: South Carolina Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Alabama Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Mississippi Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Louisiana Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Arkansas Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Kentucky Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Oklahoma Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Virginia Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Maryland Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: West Virginia Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Midwest Region U.S. Percutaneous Coronary Intervention Devices Market Share and Leading Players, 2025
FIGURE 117: Midwest Region Market Share Analysis by State, 2025
FIGURE 118: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Illinois Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Ohio Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Michigan Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: Minnesota Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: Indiana Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 124: Wisconsin Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 125: Missouri Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 126: Iowa Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 127: Kansas Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 128: Nebraska Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 129: North Dakota Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 130: South Dakota Percutaneous Coronary Intervention Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 131: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 132: Company Positioning Matrix
FIGURE 133: Key Player PCI Product and Cath Lab Platform Portfolio Benchmarking
FIGURE 134: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 135: PCI Device Innovation Roadmap
FIGURE 136: Future Market Scenario Analysis, 2026–2035
FIGURE 137: Disruptive Technologies Impact Matrix
FIGURE 138: Coronary Drug-Coated Balloon Adoption Roadmap
FIGURE 139: Intravascular Lithotripsy and Calcium Modification Opportunity Map
FIGURE 140: AI-Enhanced IVUS, OCT and Angiography-Derived Physiology Roadmap
FIGURE 141: Outpatient PCI and Same-Day Discharge Growth Roadmap
FIGURE 142: Investment Prioritization Matrix
FIGURE 143: Strategic Growth Roadmap for U.S. PCI Device Companies
FIGURE 144: U.S. Go-to-Market Strategy Framework
FIGURE 145: Product Positioning and Portfolio Expansion Framework
FIGURE 146: State and Regional Commercial Prioritization Framework
FIGURE 147: Report Scope and Disclaimer Framework